Aerie Pharmaceuticals to Present at Ophthalmology Futures Forums in Vienna, Austria

September 13, 2018

DURHAM, N.C.--(BUSINESS WIRE)--Sep. 13, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present at the Ophthalmology Futures European Forum held prior to the 36th Congress of the European Society of Cataract and Refractive Surgeons on Thursday, September 20, 2018 at 9:57 a.m. Central European Time in Vienna, Austria. Mr. Rubino will provide an Aerie overview and business update.

A copy of Mr. Rubino's presentation will be available on Aerie's website at http://investors.aeriepharma.com/after the close of market on Wednesday, September 19.

In addition, Theresa Heah, M.D., M.B.A., Vice President of Clinical Research, Medical and Professional Affairs, will be presenting at the Ophthalmology Futures Retina Forum on Wednesday, September 19, at 5:55 p.m. Central European Time, and Casey Kopczynski, Ph.D., Chief Scientific Officer, will participate in an expert panel on glaucoma drug delivery at the Ophthalmology Futures European Forum at 9:20 a.m. Central European Time on September 20.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eyedrop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, cornea verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie's advanced-stage product candidate, Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, achieved its 3-month primary efficacy endpoint in two Phase 3 registration trials, Mercury 1 and Mercury 2, and also showed safety and efficacy throughout 12 months in Mercury 1. Aerie submitted the Roclatan™ New Drug Application (NDA) in May 2018 and, in July 2018, the FDA set the PDUFA (Prescription Drug User Fee Act) goal date for the completion of the FDA's review of the Roclatan ™ NDA for March 14, 2019. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180913005009/en/

Source: Aerie Pharmaceuticals, Inc.

Aerie Pharmaceuticals
Media:
Tad Heitmann, 949-526-8747
theitmann@aeriepharma.com
or
Investors:
Richard Rubino, 908-947-3540
rrubino@aeriepharma.com
or
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals
Investors:
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com